Advertisement
ACB vs COSM
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACB is a Hold and COSM is a Buy.
ACB's RSI Indicator peaks and leaves overbought zone
The 10-day RSI Indicator for ACB moved out of overbought territory on October 07, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 17 instances where the indicator moved out of the overbought zone. In 17 of the 17 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for ACB turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 42 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
The 10-day moving average for ACB crossed bearishly below the 50-day moving average on October 27, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
ACB broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 66 cases where ACB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on ACB as a result. In 71 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
ACB moved above its 50-day moving average on October 27, 2026 date and that indicates a change from a downward trend to an upward trend.
The 50-day moving average for ACB moved above the 200-day moving average on September 30, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +6.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACB advanced for three days, in 179 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 82 of 116 cases where ACB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 71%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.488) is normal, around the industry mean (8.329). P/E Ratio (-2.093) is within average values for comparable stocks, (-1.568). Projected Growth (PEG Ratio) (0.020) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (0.984) is also within normal values, averaging (178.797).
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. ACB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
COSM's RSI Indicator recovers from oversold territory
The RSI Oscillator for COSM moved out of oversold territory on October 27, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 42 similar instances when the indicator left oversold territory. In 38 of the 42 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 58 of 64 cases where COSM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
COSM moved above its 50-day moving average on October 30, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +23.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where COSM advanced for three days, in 191 of 220 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
COSM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on COSM as a result. In 89 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for COSM turned negative on October 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 38 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
The 10-day moving average for COSM crossed bearishly below the 50-day moving average on October 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where COSM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for COSM entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.499) is normal, around the industry mean (12.349). P/E Ratio (-0.460) is within average values for comparable stocks, (10.611). Projected Growth (PEG Ratio) (0.850) is also within normal values, averaging (2.016). Dividend Yield (0.000) settles around the average of (0.141) among similar stocks. P/S Ratio (0.160) is also within normal values, averaging (4.260).
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating fairly steady price growth. COSM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 81 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. COSM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock worse than average.
ACB | COSM | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 24 Undervalued | 38 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 96 | 99 | |
PRICE GROWTH RATING 1..100 | 41 | 63 | |
P/E GROWTH RATING 1..100 | 92 | 81 | |
SEASONALITY SCORE 1..100 | 12 | 21 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ACB's Valuation (24) in the Pharmaceuticals Other industry is in the same range as COSM (38) in the null industry. This means that ACB’s stock grew similarly to COSM’s over the last 12 months.
ACB's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as COSM (100) in the null industry. This means that ACB’s stock grew similarly to COSM’s over the last 12 months.
ACB's SMR Rating (96) in the Pharmaceuticals Other industry is in the same range as COSM (99) in the null industry. This means that ACB’s stock grew similarly to COSM’s over the last 12 months.
ACB's Price Growth Rating (41) in the Pharmaceuticals Other industry is in the same range as COSM (63) in the null industry. This means that ACB’s stock grew similarly to COSM’s over the last 12 months.
COSM's P/E Growth Rating (81) in the null industry is in the same range as ACB (92) in the Pharmaceuticals Other industry. This means that COSM’s stock grew similarly to ACB’s over the last 12 months.
| ACB | COSM | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 90% | 3 days ago 90% |
| Stochastic ODDS (%) | 3 days ago 77% | 3 days ago 90% |
| Momentum ODDS (%) | 3 days ago 79% | 3 days ago 90% |
| MACD ODDS (%) | 3 days ago 90% | 3 days ago 90% |
| TrendWeek ODDS (%) | 3 days ago 81% | 3 days ago 89% |
| TrendMonth ODDS (%) | 3 days ago 78% | 3 days ago 90% |
| Advances ODDS (%) | 6 days ago 76% | 3 days ago 87% |
| Declines ODDS (%) | 14 days ago 84% | 11 days ago 90% |
| BollingerBands ODDS (%) | 3 days ago 90% | 3 days ago 89% |
| Aroon ODDS (%) | 3 days ago 71% | 3 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ACB’s FA Score shows that 1 FA rating(s) are green while COSM’s FA Score has 0 green FA rating(s).
- ACB’s FA Score: 1 green, 4 red.
- COSM’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ACB’s TA Score shows that 6 TA indicator(s) are bullish while COSM’s TA Score has 5 bullish TA indicator(s).
- ACB’s TA Score: 6 bullish, 5 bearish.
- COSM’s TA Score: 5 bullish, 5 bearish.
Price Growth
ACB (@Pharmaceuticals: Generic) experienced а +4.64% price change this week, while COSM (@Medical Distributors) price change was +17.97% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.14%. For the same industry, the average monthly price growth was -9.43%, and the average quarterly price growth was +3.28%.
The average weekly price growth across all stocks in the @Medical Distributors industry was +1.68%. For the same industry, the average monthly price growth was -7.47%, and the average quarterly price growth was -23.70%.
Reported Earning Dates
ACB is expected to report earnings on Nov 12, 2026.
COSM is expected to report earnings on Nov 13, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-0.14% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
@Medical Distributors (+1.68% weekly)Healthcare distribution market can be segmented into pharmaceutical product distribution services, medical device distribution services, and biopharmaceutical product distribution services. In addition to serving as intermediaries, many medical distributors also purchase and take legal ownership of pharmaceuticals and manage inventory and credit risk. According to a Deloitte report, pharmaceutical distributors’ core services of efficient product distribution, inventory management, financial risk management, and information-sharing generate $33 billion-$53 billion in value annually to the U.S. health care ecosystem. Some prominent players in the overall medical distribution industry include McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and Patterson Companies, Inc.
Advertisement
COSM and
Correlation & Price change
A.I.dvisor tells us that COSM and HKPD have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that COSM and HKPD's prices will move in lockstep.
| Ticker / NAME | Correlation To COSM | 1D Price Change % | ||
|---|---|---|---|---|
| COSM | 100% | +10.95% | ||
| HKPD - COSM | 21% Poorly correlated | -10.96% | ||
| SUPN - COSM | 20% Poorly correlated | +0.19% | ||
| OGI - COSM | 16% Poorly correlated | -2.85% | ||
| INCR - COSM | 14% Poorly correlated | -0.75% | ||
| ACB - COSM | 13% Poorly correlated | -0.49% | ||
More | ||||